Skinvisible, Inc., together with its subsidiaries, focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over-the-counter, personal skincare, and cosmetic markets. Its non-dermatological formulations offer solutions for women's health, pain management, and others markets. The company offers sunless tanning, anti-aging, and sunscreen products. Skinvisible, Inc. also licenses its products to manufacturers and marketers of brands internationally, as well as sells directly in the market; assists pharmaceutical clients in the early development of the formulations; and provides solutions to pharmaceutical companies by reformulating their products coming off patent with a new Invisicare patent, and new product benefits and line extensions. The company was formerly known as Microbial Solutions, Inc. and changed its name to Skinvisible, Inc. in February 1999. Skinvisible, Inc. was founded in 1998 and is based in Las Vegas, Nevada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone702-433-7154
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$630,000.00
Profitability
Miscellaneous
Employees3
Next Earnings Date5/21/2019 (Estimated)
OptionableNot Optionable
Skinvisible (OTCMKTS:SKVI) Frequently Asked Questions
What is Skinvisible's stock symbol?
Skinvisible trades on the OTCMKTS under the ticker symbol "SKVI."
When is Skinvisible's next earnings date?
Has Skinvisible been receiving favorable news coverage?
Headlines about SKVI stock have trended positive recently, according to InfoTrie Sentiment. The research group scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Skinvisible earned a media sentiment score of 2.9 on InfoTrie's scale. They also gave news stories about the company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Who are some of Skinvisible's key competitors?
Some companies that are related to Skinvisible include Boston Therapeutics (BTHE), Global Future City (FTCY), Anthera Pharmaceuticals (ANTH), Synergy Pharmaceuticals (SGYP), Cotinga Pharmaceuticals (COTQF), American Bio Medica (ABMC), RXi Pharmaceuticals (RXII), Capstone Therapeutics (CAPS), Aoxing Pharmaceutical (AOXG), Myrexis (MYRX), Affymax (AFFY), Argos Therapeutics (ARGSQ), Pernix Therapeutics (PTX), Biostar Pharmaceuticals (BSPM) and Mabvax Therapeutics (MBVX).
What other stocks do shareholders of Skinvisible own?
Who are Skinvisible's key executives?
Skinvisible's management team includes the folowing people:
- Mr. Terry H. Howlett, Pres, CEO, CFO & Director (Age 71)
- Ms. Doreen McMorran, VP of Bus. Devel. (Age 56)
- Dr. Geert Cauwenbergh, Head of International Advisory Board (Age 65)
How do I buy shares of Skinvisible?
Shares of SKVI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Skinvisible's stock price today?
One share of SKVI stock can currently be purchased for approximately $0.2251.
How big of a company is Skinvisible?
Skinvisible has a market capitalization of $652,790.00 and generates $630,000.00 in revenue each year. Skinvisible employs 3 workers across the globe.
What is Skinvisible's official website?
How can I contact Skinvisible?
Skinvisible's mailing address is 6320 S SANDHILL ROAD SUITE 10, LAS VEGAS NV, 89120. The company can be reached via phone at 702-433-7154 or via email at [email protected]
MarketBeat Community Rating for Skinvisible (OTCMKTS SKVI)
MarketBeat's community ratings are surveys of what our community members think about Skinvisible and other stocks. Vote "Outperform" if you believe SKVI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SKVI will underperform the S&P 500 over the long term. You may vote once every thirty days.
